Wikipedia -WSS

Wikipedia

author：knowledge 2025-08-04 12:35:58 - browse：21

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The FDA must approve intranasal treatments for anaphylaxis

entertainment

knowledge

WSS

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

A solution to the after

Alabama IVF ruling threatens families facing fatal genetic disease

A new nitrogen execution bill also undermines medical licensing

Alabama hospital puts IVF treatments on hold

Chronically ill young patients struggle to find fertility info

explore

Wikipedia

explore

Jerome Adams on the need for new antivirals for Covid

UCB departs biotech trade group BIO

Heart attack and stroke risk calculators need revising

NIH study of ME/CFS points to clear biological hallmarks

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

3 medical device trends to watch in 2024

In Memoriam: Notable people who died in 2023

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Continuity nursing helped my family in our darkest PICU moments

Alabama IVF ruling threatens families facing fatal genetic disease

leisure time

With competition flaring, obesity drug hits goal in liver disease study

Obesity drugs seen as possible treatment for liver disease MASH

Obesity drugs seen as possible treatment for liver disease MASH

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

With competition flaring, obesity drug hits goal in liver disease study

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

entertainment

entertainment

knowledge

focus